-
CAREGIVER PRODUCTIVITY LOSS AND HEALTH-RELATED QUALITY OF LIFE ASSOCIATED WITH PEDIATRIC RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREA
Mar 18, 2026, 21:38 PM -
MEASURING ADHERENCE TO, AND PERSISTENCE WITH, ADVANCED THERAPY IN PATIENTS WITH LUPUS NEPHRITIS IN THE REAL-WORLD SETTING
Mar 18, 2026, 21:38 PM -
UNDERSTANDING THE HEALTH-RELATED QUALITY OF LIFE BURDEN IN CHRONIC HEPATITIS DELTA INFECTION: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
COST OF CARE AND BUDGET IMPACT OF FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FROM THE MEXICAN PUBLIC PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
NATURAL HISTORY, MANAGEMENT, AND BURDEN OF DISEASE IN ADULTS WITH NF1 AND SYMPTOMATIC INOPERABLE PLEXIFORM NEUROFIBROMA IN FRANCE
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN
Mar 18, 2026, 21:38 PM -
COMPARATIVE ANALYSIS OF GENE THERAPIES AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
Mar 18, 2026, 21:38 PM -
INTERPRETABLE MACHINE LEARNING TO PREDICT CATASTROPHIC HEALTH EXPENDITURE RISK IN CHINA: EVIDENCE FROM NATIONALLY REPRESENTATIVE SURVEY DATA
Mar 18, 2026, 21:38 PM -
DISTINGUISHING AI FROM AUTOMATION IN HEOR: LESSONS FROM OTHER INDUSTRIES
Mar 18, 2026, 21:38 PM -
BRIDGING HER2 TESTING AND TREATMENT: REAL-WORLD EVIDENCE ACROSS 22 SOLID TUMORS
Mar 18, 2026, 21:38 PM -
NEUROLOGIST PREFERENCES FOR NEW MS TREATMENTS: IMPLICATIONS FOR MARKET ACCESS PRIORITIZATION IN THE UNITED STATES AND EUROPE
Mar 18, 2026, 21:38 PM -
TRANSLATION AND PSYCHOMETRIC EVALUATION OF THE YORUBA VERSION OF IBADAN LOW-BACK PAIN DISABILITY QUESTIONNAIRE
Mar 18, 2026, 21:38 PM -
CHARACTERIZING REAL-WORLD DISEASE BURDENS IN CARDIAC AMYLOIDOSIS: A DESCRIPTIVE STUDY ON SOCIAL, ECONOMIC, AND ACCESS-RELATED IMPACTS ON PATIENTS IN GERMANY AND SPAIN
Mar 18, 2026, 21:38 PM -
DISEASE PERCEPTION, QUALITY OF LIFE, AND MENTAL HEALTH OF NEWLY DIAGNOSED AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)-ELIGIBLE MULTIPLE MYELOMA PATIENTS FROM A TERTIARY CARE HOSPITAL IN CHINA: A CROSS-SECTIONAL SURVEY STUDY
Mar 18, 2026, 21:38 PM -
AI ENABLED RWE CODE REFACTORING OF ANALYTICS PIPELINE
Mar 18, 2026, 21:38 PM -
FORMULARY EXCLUSIONS AND NON-ADHERENCE TO DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS IN MEDICARE PART D
Mar 18, 2026, 21:38 PM -
USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS
Mar 18, 2026, 21:38 PM -
FROM RETRIEVAL TO VERDICT: A HYBRID LLM PIPELINE FOR EVALUATING MEDICAL AND ECONOMIC CLAIMS
Mar 18, 2026, 21:38 PM -
METHODOLOGICAL CHARACTERISTICS OF PHARMACOGENOMICS-INTEGRATED AI CLINICAL DECISION SUPPORT SYSTEMS (AI-CDSS): A SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
TEPROTUMUMAB VERSUS INTRAVENOUS METHYLPREDNISOLONE ALONE, AND IN COMBINATION WITH MYCOPHENOLATE MOFETIL, FOR MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE: A MATCHING-ADJUSTED INDIRECT COMPARISON
Mar 18, 2026, 21:38 PM
